Restoring vision by correcting genetic mutations in the eye
Restoring Vision with High-Fidelity Nonsense Codon Correction
This study is testing a new treatment for inherited eye diseases that cause vision loss by using a special therapy to help your eyes make the right proteins, and it's designed for people with specific genetic conditions that lead to blindness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project ID | NIH-11003268 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for inherited eye diseases caused by nonsense mutations, which lead to severe vision loss. The approach involves using a novel type of nucleic acid therapy that delivers a specific transfer RNA to the eye, allowing for the correct amino acids to be incorporated during protein production. By targeting the underlying genetic issues, this therapy aims to restore normal function in the affected cells. The research will explore the effectiveness of this treatment in various genetic conditions that cause blindness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with inherited retinopathies caused by nonsense mutations, particularly those affecting ion channel proteins.
Not a fit: Patients with retinopathies not caused by nonsense mutations or those with other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a groundbreaking therapy that restores vision for patients with specific genetic mutations.
How similar studies have performed: While there are limited therapies currently being tested for nonsense mutations, the innovative approach of using ace-tRNA is relatively novel and has not been widely implemented in clinical settings.
Where this research is happening
Madison, United States
- University of Wisconsin-Madison — Madison, United States (Active)
Researchers
- Principal investigator: Pattnaik, Bikash Ranjan — University of Wisconsin-Madison
- Study coordinator: Pattnaik, Bikash Ranjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.